Our Services

Blood Cancer

Chronic lymphocytic leukemia and multiple myeloma, blood cancers, represent a large group of different malignancies. This group includes cancers of the bone marrow, blood, and lymphatic system, which includes lymph nodes, lymphatic vessels, tonsils, thymus, spleen, and digestive tract lymphoid tissue. Leukemia and myeloma, which start in the bone marrow, and lymphoma, which starts in the lymphatic system, are the most common types of blood cancer. What causes these cancers is not known.

Blood Cancer: Leukemia

Novel Btk Inhibitor for Previously Treated Patients with Chronic Lymphocytic Leukemia (CLL) Clinical Trial

  • All patients receive treatment: ACP196 (Btk Inhibitor) or Ibrutinib
  • Patients need to have finished at least one prior treatment for CLL
  • Main study doctor (Principal Investigator): Jarrod Holmes, MD
  • For more information, please contact the lead coordinator, Catherine Hollister, at 707-521-3808 or at Catherine.Hollister@stjoe.org

A Disease Registry for Patients with Chronic Lymphocytic Leukemia (CLL)

  • Study name: informCLL™
  • No treatment
  • Patients complete questionnaires to help physicians better understand current treatment patterns for CLL in the real-world setting
  • Main study doctor (Principal Investigator): Wes Lee, MD
  • For more information, please contact the lead coordinator, Anthony Blackburn, at 707-521-3809 or at Anthony.Blackburn@stjoe.org.

Blood Cancer: Multiple Myeloma

Pomalidomide and Low-dose Dexamethasone Plus or Minus Immunotherapy for Refractory or Relapsed Multiple Myeloma Clinical Trial

  • ON HOLD
  • Study name: “Keynote 183”
  • Patients are randomized in a 1:1 ratio: Pomalidomide + low-dose Dexamethasone + Pembrolizumab (Keytruda) vs. Pomalidomide + low-dose Dexamethasone
  • Patients must have failed at least 2 prior lines of treatment or are refractory and failed their last line of therapy
  • Main study doctor (Principal Investigator): Wes Lee, MD
  • For more information, please contact the lead coordinator, Tracy Foster, at 707-521-3836 or at Tracy.Foster@stjoe.org

Lenalidomide and Low-dose Dexamethasone Plus or Minus Immunotherapy for Refractory or Relapsed Multiple Myeloma Clinical Trial

  • ON HOLD
  • Study name: “Keynote 185”
  • All patients receive treatment
  • Patients are randomized to treatment arms in a 1:1 ratio: Lenalidomide + low-dose Dexamethasone + Pembrolizumab (Keytruda) vs. Lenalidomide + low-dose Dexamethasone
  • Patients must be newly diagnosed and treatment naïve
  • Main study doctor (Principal Investigator): Wes Lee, MD
  • For more information, please contact the lead coordinator, Tracy Foster, at 707-521-3836 or at Tracy.Foster@stjoe.org

Multiple Myeloma (MM) RegistryStudy

  • Study name: INSIGHT-MM
  • No treatment
  • Patients complete questionnaires to help physicians better understand current treatment patterns for MM in the real-world setting
  • No treatment is given in this study
  • Main study doctor (principal investigator): Ian Anderson, MD
  • For more information, please contact the lead coordinator, Anthony Blackburn, at 707-521-3809 or at Anthony.Blackburn@stjoe.org

Myelofibrosis (MF) and Essential Thrombocythemia (ET) Registry

  • Study name: MOST
  • No treatment
  • Patients complete questionnaires to help physicians better understand current treatment patterns for MF and ET in the real-world setting
  • No treatment is given in this study
  • Main study doctor (principal investigator): Ian Anderson, MD
  • For more information, please contact the lead coordinator, Catherine Hollister, at 707-521-3808 or at Catherine.Hollister@stjoe.org